Plasma concentrations of osteoprotegerin during normoand hyperglycaemic clamping

被引:26
作者
Knudsen, S. T. [1 ]
Jeppesen, P.
Poulsen, P. L.
Andersen, N. H.
Bek, T.
Schmitz, O.
Mogensen, C. E.
Rasmussen, L. M.
机构
[1] Aarhus Univ Hosp, Med Dept Diabet & Endocrinol M, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Dept Clin Biochem, DK-8000 Aarhus C, Denmark
关键词
atherosclerosis; blood glucose; diabetes; insulin; metabolic control; OPG; vascular calcifications;
D O I
10.1080/00365510600987728
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective. Plasma levels of osteoprotegerin (OPG) are elevated in subjects with diabetes as well as in non-diabetic subjects with cardiovascular disease. In previous studies a positive correlation was found between plasma levels of OPG and markers of glycaemic control in diabetic subjects. The aim of the present study was to examine the effect of acute hyperglycaemia on plasma levels of OPG in nondiabetic subjects. Material and methods. Nine healthy, lean, male subjects were examined in a randomized, blinded, cross-over study design during hyperglycaemic (plasma glucose=15 mmol/L, study H) as well as during euglycaemic (plasma glucose=5 mmol/L, study E) conditions. Blood samples were collected at baseline and at t=240 min. Results. Plasma OPG decreased slightly during study H (1.26 +/- 0.39 versus 1.19 +/- 0.35 ng/mL, p<0.05), whereas the level did not change significantly during study E (1.40 +/- 0.46 ng/mL versus 1.57 +/- 0.50 ng/mL, NS). The decrease in plasma OPG during hyperglycaemia did not correlate with the change in plasma glucose but correlated significantly with changes in serum insulin (r=-0.70, p=0.038). Conclusions. Acute hyperglycaemia does not seem to increase plasma levels of OPG in non-diabetic subjects, whereas hyperinsulinaemia may suppress plasma levels of OPG. This finding indicates that the elevated plasma levels of OPG observed in diabetic subjects with poor metabolic control cannot be ascribed to hyperglycaemia per se.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 17 条
[1]   The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects [J].
Anand, DV ;
Lahiri, A ;
Lim, E ;
Hopkins, D ;
Corder, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (09) :1850-1857
[2]  
ANDERSEN L, 1993, CLIN CHEM, V39, P578
[3]   Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients [J].
Avignon, A ;
Sultan, A ;
Piot, C ;
Elaerts, S ;
Cristol, JP ;
Dupuy, AM .
DIABETES CARE, 2005, 28 (09) :2176-2180
[4]   Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women [J].
Browner, WS ;
Lui, LY ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :631-637
[5]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[6]   Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques [J].
Dhore, CR ;
Cleutjens, JPM ;
Lutgens, E ;
Cleutjens, KBJM ;
Geusens, PPM ;
Kitslaar, PJEHM ;
Tordoir, JHM ;
Spronk, HMH ;
Vermeer, C ;
Daemen, MJAP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (12) :1998-2003
[7]   Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease [J].
Jono, S ;
Ikari, Y ;
Shioi, A ;
Mori, K ;
Miki, T ;
Hara, K ;
Nishizawa, Y .
CIRCULATION, 2002, 106 (10) :1192-1194
[8]   Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications [J].
Knudsen, ST ;
Foss, CH ;
Poulsen, PL ;
Andersen, NH ;
Mogensen, CE ;
Rasmussen, LM .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 149 (01) :39-42
[9]   Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells [J].
Malyankar, UM ;
Scatena, M ;
Suchland, KL ;
Yun, TJ ;
Clark, EA ;
Giachelli, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :20959-20962
[10]   Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis [J].
Min, H ;
Morony, S ;
Sarosi, I ;
Dunstan, CR ;
Capparelli, C ;
Scully, S ;
Van, G ;
Kaufman, S ;
Kostenuik, PJ ;
Lacey, DL ;
Boyle, TJ ;
Simonet, WS .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :463-474